Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale

Masato Nakamura,Shinsuke Nanto,Atsushi Hirayama,Tadateru Takayama,Masakatsu Nishikawa,Kazuo Kimura,Satoshi Morita,Tadanori Aizawa,Ryuta Asano,Yuji Matsumaru,Chikuma Hamada,Takaaki Isshiki,OPERA Steering Committee and Investigators,Takahide Suzuki,Junya Ako,Nobuhiro Omura,Kenji Yamazaki,Hiroyuki Ando,Junji Yajima,Yutaro Nishi,Hiroshi Ohta,Itaru Takamizawa,Hiroyuki Kyono,Takayuki Ogawa,Taro Kawano,Katsumi Miyauchi,Hajime Fujimoto,Shinichi Usui,Jiro Ando,Naoki Nozaki,Yoshihide Fujimoto,Junji Kanda,Kiyoshi Hibi,Masakazu Nagaoka,Itaru Yokouchi,Hideto Yano,Kazuki Fukui,Teruyasu Sugano,Ken Kongoji,Kazuhiko Misu,Masahiro Yamauchi,Kouichi Mizuno,Taiki Tojo,Yota Kawamura,Toshiya Muramatsu,Naoyuki Okada,Masakazu Kobayashi,Munenori Okubo,Hideo Nishikawa,Takashi Tanikawa,Masatoshi Miyahara,Tetsuya Kitamura,Masakazu Yamagishi,Kazuo Osato,Noriyuki Shirasaka,Mitsuo Takeda,Hiroshi Fujita,Akihiro Shirasaka,Ryuta Sakai,Tomonori Amano,Eisho Kyo,Eigi Ogura,Masaharu Okada,Kan Zen,Jin Nariyama,Yutaka Morita,Yuji Sakagami,Isao Morii,Masumi Shimizu,Atsushi Nakagawa,Shigeo Kawano,Noritoshi Ito,Toru Kataoka,Haruyuki Taguchi,Masaya Miyagawa,Masahiro Kumada,Kenji Fujii,Takashi Morita,Yasunori Ueda,Shozo Ishihara,Junichi Kotani,Shinji Nakata,Hiroshi Kamahara,Ryushi Komatsu,Rei Fukuhara,Natsuhiko Ehara,Hiroshi Okamoto,Kenichi Fujii,Katsumi Oka,Kojiro Awano,Masaki Awata,Morihiko Kondo,Atsushi Hirohata,Shinji Sato,Hiroyuki Okura,Makoto Nakahama,Hiromichi Tamekiyo,Hiroki Terakawa,Yoshiyuki Furuse,Michio Yamada,Yoichi Kishi,Yasuo Komura,Nobuhiro Suematsu,Akihiro Koike,Yohsuke Katsuda,Kiyoshi Hironaga,Shinjo Sonoda,Yutaka Hikichi,Kenji Horiuchi,Kazuteru Fujimoto,Katsuo Noda,Koji Maemura,Hiroshi Yamaguchi,Keishi Saihara,Koichi Oshiro,Hiroki Uehara,Koji Kajiwara

DOI: https://doi.org/10.1002/ccd.25282

2014-09-01

Abstract:Background: In patients with coronary artery disease (CAD), there is an increasing therapeutic need among interventional cardiologists to conduct dual antiplatelet therapy (DAPT) whose duration is shorter than current guideline-recommended 6-12 months after the implantation of drug-eluting stents. However, no clinical grounds sufficient to rationalize the need are available. Objectives: To define the optimal duration of DAPT and to examine the safety and efficacy of the Endeavor zotarolimus-eluting stent (E-ZES) in real-world Japanese patients with CAD. Study design: The present prospective, nonrandomized, multicenter, controlled study is uniquely designed to examine the analysis set to be formulated after integrating two different databases consisting of the following two study arms: the 3-month DAPT arm, in which 1,210 patients were consecutively enrolled at 106 medical institutions; and the 12-month DAPT arm, in which 1,210 patients will be consecutively extracted from the Endeavor Japan post-marketing surveillance at 60 medical institutions. The primary endpoint is "net adverse cardiac and cerebrovascular events-death, myocardial infarction, cerebrovascular accident, and major bleeding)" at 12 months after implantation. The secondary endpoints are as follows: major adverse cardiac events at 1, 3, 6, 9, and 12 months after implantation; target vessel revascularization and target lesion revascularization at 9 and 12 months after implantation; and stent thrombosis, DAPT compliance, and bleeding events at 12 months after implantation. Noninferiority in the E-ZES's profiles between the study arms will be investigated. Conclusions: The present study will provide insight into the optimal duration of DAPT after the E-ZES implantation in individual, real-world patients with CAD.